It’s all about the numbers23 Feb 2021 20:20
I’ve looked at the RNS of 13th January and for me it’s all about the numbers
In simplistic terms Vlad is saying that we have developed a CDX antibody which ticks the boxes for moving onto clinical trials and whilst we are in negotiations to agree a deal with the “Global” company we are continuing to crack on developing this CDX antibody asset WITH the “global “ company .
Which tells me the global company seems fairly friggin happy to continue developing the “asset” (which they have already spent 30 months trying to perfect with Hemo) whilst they get their team of accountants on the job doing some number crunching to get a deal over the line. It’s all about the numbers nothing else in my eyes..........
A few lines from 13th Jan-
“the Directors are confident that a successful outcome will be achieved to take the development of the CDX antibody forward toward clinical trials. In the meantime, the Company and GlobalCo will continue developing the CDX antibody asset.
We are extremely pleased with the outcome of our collaboration with GlobalCo, which has resulted in a CDX antibody that is ready to be developed for clinical trials. I am very proud of the Company's team of scientists who, without a doubt, have proven that Hemogenyx Pharmaceuticals is capable of performing cutting edge research and development of the highest calibre. The completion of the development of the CDX antibody with GlobalCo is a key milestone on our path to creating an effective treatment for patients suffering from AML, and we look forward to entering into the next phase of negotiations with GlobalCo."
Good luck all and keep the faith..........